my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
22-02-2010: Cellectis and Genoway indicate that the sublicense agreement dated September 7, 2001, relating to the patents and patent applications belonging to the pool WO90/11354 has been terminated as of December 30, 2008.
Cellectis and Genoway have agreed on the consequences of such termination of the sublicense agreement, allowing Genoway to deliver the orders placed after the termination and before November 12, 2009. A visa of Cellectis will be attached to the delivery of such orders. Cellectis and Genoway have therefore amicably and definitely closed their disagreement.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
genOway reported an agreement with the Griffith University on a eight-months research partnership with its Eskitis Institute for Cell and Molecular Therapies focusing on autologous olfactory adult stem cells. This research program is coupled with a world wide exclusive license to genOway fo ... more
Cellectis and Genoway close their disagreement
Cellectis and Genoway indicate that the sublicense agreement dated September 7, 2001, relating to the patents and patent applications belonging to the pool WO90/11354 has been terminated as of December 30, 2008. Cellectis and Genoway have agreed on the consequences of such termination of t ... more
genOway and Boehringer Ingelheim reinforce their collaboration
genOway reports a collaboration with Boehringer Ingelheim for the development of experimental research models. This collaboration has been recently reinforced and now includes several innovative technological solutions developed by genOway to create more powerful research models. genOway u ... more
The development of a new drug costs roughly 800 M.USD. This huge investment has to cover both the development of the drug itself and the cost of unfruitful work. Dead-ends can represent up to 80% of the total cost of a successful drug. Major challenges in the drug development process are (1 ... more
The development of a new drug costs roughly 800 M.USD. This huge investment has to cover both the development of the drug itself and the cost of unfruitful work. Dead-ends can represent up to 80% of the total cost of a successful drug. Major challenges in the drug development process are (1 ... more
Medicago Inc. and Cellectis plant sciences, a subsidiary of Cellectis SA announced the signing of a research agreement under which Medicago and Cellectis will collaborate to improve therapeutic proteins expressed from tobacco leaves. "We look forward to working with Cellectis plant science ... more
Cellectis’ Meganuclease Technology Used to Efficiently Prevent Viral Infection
Cellectis announced that scientists from Cellectis therapeutics, the French National Center For Medical Research (CNRS) and Institut de la Vision (Paris) have used its proprietary meganucleases to successfully prevent infection of cultured cells by a Herpes Simplex virus (HSV-1). The resea ... more
Cellectis and the Center for iPS Cells Research and Application enter collaboration
Cellectis and the Center for iPS Cells Research and Application (CiRA) of Kyoto University, Kyoto, Japan, have announced that they have started a scientific collaboration to combine Cellectis’ genome engineering technologies with CiRA’s induced pluripotent stem cell (iPS) technology to impr ... more
Cellectis is the worldwide leader in the research, development and commercialization of rational genome engineering technologies. Cellectis proprietary technologies and platform are based upon a naturally occurring class of DNA endonucleases, the Meganucleases and DNA recombination. The DNA ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
